Published in Clin Liver Dis on November 01, 2007
Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol (2008) 3.34
The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis (2011) 2.96
Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol (2013) 2.44
Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int (2010) 1.03
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int (2012) 0.98
Assessment of liver fibrosis by transient elastography in patients with HIV and hepatitis B virus coinfection in Nigeria. Clin Infect Dis (2013) 0.94
Hepatitis B management in vulnerable populations: gaps in disease monitoring and opportunities for improved care. Dig Dis Sci (2013) 0.94
Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. World J Gastroenterol (2010) 0.90
Hepatitis B Virus Infection during Pregnancy: Transmission and Prevention. Middle East J Dig Dis (2011) 0.86
Tenascin-C expression is associated with poor prognosis in hepatocellular carcinoma (HCC) patients and the inflammatory cytokine TNF-α-induced TNC expression promotes migration in HCC cells. Am J Cancer Res (2015) 0.83
Recent advances in micro/nanotechnologies for global control of hepatitis B infection. Biotechnol Adv (2014) 0.81
Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents. J Korean Med Sci (2014) 0.80
Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci (2014) 0.79
Is it more cost-effective for patients with chronic hepatitis b to have a trial of interferon before considering Nucleos(t)ide analogue therapy? Clin Gastroenterol Hepatol (2014) 0.78
Risk Factors for the Development of Hepatocellular Carcinoma in Thailand. J Clin Transl Hepatol (2015) 0.78
Overrepresentation of IL-10-Expressing B Cells Suppresses Cytotoxic CD4+ T Cell Activity in HBV-Induced Hepatocellular Carcinoma. PLoS One (2016) 0.77
Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int (2017) 0.77
Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol (2011) 0.76
Reasons why West Africa continues to be a hotbed for hepatocellular carcinoma. Niger Med J (2016) 0.75
In Vitro Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across Genotypes. J Virol (2016) 0.75
The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir. Hepat Mon (2016) 0.75
A major shift of viral and nutritional risk factors affects the hepatocellular carcinoma risk among Ivorian patients: a preliminary report. Infect Agent Cancer (2015) 0.75
Brief Report: HIV/HBV Coinfection is a Significant Risk Factor for Liver Fibrosis in Tanzanian HIV-Infected Adults. J Acquir Immune Defic Syndr (2017) 0.75
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 6.67
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol (2010) 3.55
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis (2012) 3.22
Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology (2008) 2.46
Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. Am J Epidemiol (2013) 2.44
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm (2008) 2.16
Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res (2007) 2.02
Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology (2009) 1.95
Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology (2010) 1.89
Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke (2010) 1.82
Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology (2010) 1.69
Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int (2009) 1.65
Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol (2013) 1.60
Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology (2011) 1.59
Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol (2011) 1.57
Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol (2006) 1.56
Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology (2013) 1.45
Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol (2010) 1.36
Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol (2007) 1.28
Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol (2011) 1.26
Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control (2003) 1.23
Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev (2009) 1.21
Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int (2012) 1.20
Cost of chronic hepatitis B infection in China. J Clin Gastroenterol (2004) 1.14
Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol (2010) 1.05
Global DNA methylation levels in white blood cells as a biomarker for hepatocellular carcinoma risk: a nested case-control study. Carcinogenesis (2012) 1.04
Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. Int J Epidemiol (2005) 1.01
Epidemiology of virus infection and human cancer. Recent Results Cancer Res (2014) 0.96
Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-2. Gut (2010) 0.95
211 G to a variation of UDP-glucuronosyl transferase 1A1 gene and neonatal breastfeeding jaundice. Pediatr Res (2011) 0.94
Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS One (2013) 0.93
Urinary 8-oxodeoxyguanosine, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcinogenesis (2006) 0.93
Urinary 15-F2t-isoprostane, aflatoxin B1 exposure and hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Carcinogenesis (2008) 0.93
Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol (2004) 0.93
Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. Leuk Res (2012) 0.91
Polycyclic aromatic hydrocarbon- and aflatoxin-albumin adducts, hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Cancer Lett (2007) 0.88
Chronic hepatitis B infection and risk of atherosclerosis-related mortality: A 17-year follow-up study based on 22,472 residents in Taiwan. Atherosclerosis (2010) 0.88
Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis (2005) 0.87
Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. Ann Med (2004) 0.87
Preeclampsia and the risk of bronchopulmonary dysplasia in VLBW infants: a population based study. PLoS One (2013) 0.86
A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. J Hepatol (2012) 0.86
96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic) (2010) 0.86
Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma. Int J Cancer (2014) 0.85
Global DNA methylation in a population with aflatoxin B1 exposure. Epigenetics (2013) 0.85
Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One (2013) 0.85
Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care (2011) 0.84
Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B. Clin Gastroenterol Hepatol (2011) 0.83
Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PLoS One (2012) 0.83
A hospital-based study of clinical and genetic features of Crohn's disease. J Formos Med Assoc (2011) 0.82
Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol (2004) 0.82
Lifetime risk of distinct upper aerodigestive tract cancers and consumption of alcohol, betel and cigarette. Int J Cancer (2014) 0.81
Distinct seromarkers predict different milestones of chronic hepatitis B progression. Hepatology (2014) 0.80
Hepatitis B management costs in France, Italy, Spain, and the United Kingdom. J Clin Gastroenterol (2004) 0.80
Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors. Am J Cardiol (2003) 0.80
Model to predict hyperbilirubinemia in healthy term and near-term newborns with exclusive breast feeding. Pediatr Neonatol (2012) 0.79
Mediation Analysis of Hepatitis B and C in Relation to Hepatocellular Carcinoma Risk. Epidemiology (2016) 0.79
Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan. Hepatology (2015) 0.79
Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis. Medicine (Baltimore) (2016) 0.75
Causal Mediation Analysis of Survival Outcome with Multiple Mediators. Epidemiology (2017) 0.75
Author reply: To PMID 23355498. Am J Epidemiol (2013) 0.75